|
1
|
Folkman J: Seminars in medicine of the
Beth Israel Hospital, Boston. Clinical applications of research on
angiogenesis. New Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerbel R and Folkman J: Clinical
translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Kenawi AE and El-Remessy AB:
Angiogenesis inhibitors in cancer therapy: Mechanistic perspective
on classification and treatment rationales. Brit J Pharmacol.
170:712–729. 2013. View Article : Google Scholar
|
|
5
|
Burke PA and DeNardo SJ: Antiangiogenic
agents and their promising potential in combined therapy. Crit Rev
Oncol Hemat. 39:155–171. 2001. View Article : Google Scholar
|
|
6
|
Liekens S, De Clercq E and Neyts J:
Angiogenesis: Regulators and clinical applications. Biochem
Pharmacol. 61:253–270. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
OReilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lim J, Duong T, Lee G, Seong BL, El-Rifai
W, Ruley HE and Jo D: The effect of intracellular protein delivery
on the anti-tumor activity of recombinant human endostatin.
Biomaterials. 34:6261–6271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blezinger P, Wang JJ, Gondo M, Quezada A,
Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R
and Min W: Systemic inhibition of tumor growth and tumor metastases
by intramuscular administration of the endostatin gene. Nat
Biotechnol. 17:343–348. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma HI, Lin SZ, Chiang YH, Li J, Chen SL,
Tsao YP and Xiao X: Intratumoral gene therapy of malignant brain
tumor in a rat model with angiostatin delivered by adeno-associated
viral (AAV) vector. Gene Ther. 9:2–11. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma HI, Guo P, Li J, Lin SZ, Chiang YH,
Xiao X and Cheng SY: Suppression of intracranial human glioma
growth after intramuscular administration of an adeno-associated
viral vector expressing angiostatin. Cancer Res. 62:756–763.
2002.PubMed/NCBI
|
|
12
|
Daya S and Berns KI: Gene therapy using
adeno-associated virus vectors. Clin Microbiol Rev. 21:583–593.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ponnazhagan S, Curiel DT, Shaw DR, Alvarez
RD and Siegal GP: Adeno-associated virus for cancer gene therapy.
Cancer Res. 61:6313–6321. 2001.PubMed/NCBI
|
|
14
|
Davidoff AM, Nathwani AC, Spurbeck WW, Ng
CY, Zhou J and Vanin EF: rAAV-mediated long-term liver-generated
expression of an angiogenesis inhibitor can restrict renal tumor
growth in mice. Cancer Res. 62:3077–3083. 2002.PubMed/NCBI
|
|
15
|
Shi WY, Teschendorf C, Muzyczka N and
Siemann DW: Adeno-associated virus-mediated gene transfer of
endostatin inhibits angiogenesis and tumor growth in vivo. Cancer
Gene Ther. 9:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi W, Teschendorf C, Muzyczka N and
Siemann DW: Gene therapy delivery of endostatin enhances the
treatment efficacy of radiation. Radiother Oncol. 66:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ponnazhagan S, Mahendra G, Kumar S, Shaw
DR, Stockard CR, Grizzle WE and Meleth S: Adeno-associated virus
2-mediated antiangiogenic cancer gene therapy: Long-term efficacy
of a vector encoding angiostatin and endostatin over vectors
encoding a single factor. Cancer Res. 64:1781–1787. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noro T, Miyake K, Suzuki-Miyake N,
Igarashi T, Uchida E, Misawa T, Yamazaki Y and Shimada T:
Adeno-associated viral vector-mediated expression of endostatin
inhibits tumor growth and metastasis in an orthotropic pancreatic
cancer model in hamsters. Cancer Res. 64:7486–7490. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subramanian IV, Ghebre R and Ramakrishnan
S: Adeno-associated virus-mediated delivery of a mutant endostatin
suppresses ovarian carcinoma growth in mice. Gene Ther. 12:30–38.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H: Comparative observation of the
recombinant adeno-associated virus 2 using transmission electron
microscopy and atomic force microscopy. Microsc Microanal.
13:384–389. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Justus CR, Leffler N, Ruiz-Echevarria M
and Yang LV: In vitro cell migration and invasion assays. J Vis
Exp. Jun 1–2014.doi: 10.3791/51046. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puri TS, Shakaib MI, Chang A, Mathew L,
Olayinka O, Minto AW, Sarav M, Hack BK and Quigg RJ: Chronic kidney
disease induced in mice by reversible unilateral ureteral
obstruction is dependent on genetic background. Am J Physiol Renal
Physiol. 298:F1024–F1032. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mohajeri A, Sanaei S, Kiafar F, Fattahi A,
Khalili M and Zarghami N: The challenges of recombinant endostatin
in clinical application: Focus on the different expression systems
and molecular bioengineering. Adv Pharm Bull. 7:21–34. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Katz MG, Fargnoli AS, Williams RD and
Bridges CR: Gene therapy delivery systems for enhancing viral and
nonviral vectors for cardiac diseases: Current concepts and future
applications. Hum Gene Ther. 24:914–927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
OBrien T, Cranston D, Fuggle S, Bicknell R
and Harris AL: Two mechanisms of basic fibroblast growth
factor-induced angiogenesis in bladder cancer. Cancer Res.
57:136–140. 1997.PubMed/NCBI
|
|
26
|
Nguyen JT, Wu R, Clouse ME, Hlatky L and
Terwilliger EF: Adeno-associated virus-mediated delivery of
anti-angiogenic factors as an antitumor strategy. Hum Gene Ther.
10:839. 1999.
|
|
27
|
Kim YM, Jang JW, Lee OH, Yeon J, Choi EY,
Kim KW, Lee ST and Kwon YG: Endostatin inhibits endothelial and
tumor cellular invasion by blocking the activation and catalytic
activity of matrix metalloproteinase. Cancer Res. 60:5410–5413.
2000.PubMed/NCBI
|
|
28
|
Dhanabal M, Ramchandran R, Volk R,
Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M and Sukhatme
VP: Endostatin: Yeast production, mutants, and antitumor effect in
renal cell carcinoma. Cancer Res. 59:189–197. 1999.PubMed/NCBI
|
